Transformative Cancer Therapies.
Transforming the Future of Cancer Treatment
We are focused on advancing a novel class of conditionally activated proinflammatory immune modulators. These molecules are designed to act selectively within the tumor microenvironment and recruit a powerful anti-tumor immune response to deliver a clinically meaningful impact for patients.
In contrast to the modulation of immune ‘OFF’ switches such as checkpoint inhibitors, systemic therapy with proinflammatory immune modulators requires exceptional control of delivery, tissue distribution and ultimately, activation to avoid normal tissue inflammation and organ toxicity. In the past, it has been challenging to develop these agents with the appropriate pharmaceutical properties and without off-tissue toxicities.
Our team of experienced scientists embraced this challenge and established a brand-new path forward based on our proprietary platform: PREDATOR™ protein engineering technology. We are designing and engineering the future of immuno-oncology biotherapeutics for patients today.
Predator™ Protein Engineering
What’s in a name?
Our molecules are delivered systemically and remain inactive in the body as they are drawn to the tumor microenvironment, at which point they stimulate a powerful immune response and unleash an attack on cancer cells.